Operating
Stock-Based Comp
Quest Diagnostics Stock-Based Comp decreased by 20.0% to $20.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.1%, from $22.00M to $20.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 2.7% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $21.00M | $21.00M | $19.00M | $18.00M | $19.00M | $18.00M | $22.00M | $24.00M | $16.00M | $18.00M | $19.00M | $22.00M | $20.00M | $19.00M | $27.00M | $22.00M | $21.00M | $20.00M | $25.00M | $20.00M |
| QoQ Change | — | +0.0% | -9.5% | -5.3% | +5.6% | -5.3% | +22.2% | +9.1% | -33.3% | +12.5% | +5.6% | +15.8% | -9.1% | -5.0% | +42.1% | -18.5% | -4.5% | -4.8% | +25.0% | -20.0% |
| YoY Change | — | — | — | — | -9.5% | -14.3% | +15.8% | +33.3% | -15.8% | +0.0% | -13.6% | -8.3% | +25.0% | +5.6% | +42.1% | +0.0% | +5.0% | +5.3% | -7.4% | -9.1% |
Range$16.00M – $27.00M
CAGR-1.0%
Avg YoY Growth+3.4%
Median YoY Growth+0.0%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Quest Diagnostics's stock-based comp?
- Quest Diagnostics (DGX) reported stock-based comp of $20.00M in Q1 2026.
- How has Quest Diagnostics's stock-based comp changed year-over-year?
- Quest Diagnostics's stock-based comp decreased by 9.1% year-over-year, from $22.00M to $20.00M.
- What is the long-term trend for Quest Diagnostics's stock-based comp?
- Over 4 years (2021 to 2025), Quest Diagnostics's stock-based comp has grown at a 2.7% compound annual growth rate (CAGR), from $79.00M to $88.00M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.